Cargando…
Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin
Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. Despite aggressive therapy, survival outcomes remain unsatisfactory, especially for patients with metastatic disease or patients with a poor chemotherapy response. Chemoresistance contributes to treatment...
Autores principales: | De Boer, Jantine Posthuma, van Egmond, Pim W., Helder, Marco N., de Menezes, Renée X., Cleton-Jansen, Anne-Marie, Beliën, Jeroen A.M., Verheul, Henk M. W., van Royen, Barend J., Kaspers, Gert-Jan J.L., van Beusechem, Victor W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717953/ https://www.ncbi.nlm.nih.gov/pubmed/23045411 |
Ejemplares similares
-
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2011) -
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
por: PosthumaDeBoer, J, et al.
Publicado: (2013) -
Disassembly of the JIP1/JNK molecular scaffold by caspase-3-mediated cleavage of JIP1 during apoptosis
por: Vaishnav, Mahesh, et al.
Publicado: (2011) -
Syd/JIP3 and JNK Signaling Are Required for Myonuclear Positioning and Muscle Function
por: Schulman, Victoria K., et al.
Publicado: (2014) -
Acute and Chronic Hyperglycemia Elicit JIP1/JNK-Mediated Endothelial Vasodilator Dysfunction of Retinal Arterioles
por: Hein, Travis W., et al.
Publicado: (2016)